Welcome to another episode of Category Visionaries — the show that explores GTM stories from tech's most innovative B2B founders. In today's episode, we're speaking with Dimitrios Skaltsas, CEO & Co-Founder of Intelligencia AI, an AI drug development platform that's raised $15.5 Million in funding.

Here are the most interesting points from our conversation:

• Early Challenges and Inspiration: Dimitrios shared how he transitioned from McKinsey to co-founding Intelligencia AI, inspired by his work on big data and AI in pharmaceutical R&D.
• First Customer Success: Landing their first major pharmaceutical client was a pivotal moment, achieved through relentless networking and demonstrating their AI's potential to transform drug development.
• Impact of COVID-19: The pandemic accelerated the pharmaceutical industry's adoption of AI, highlighting the need for faster and more efficient drug development processes.
• Explaining AI in Pharma: Intelligencia AI stands out by focusing on explainability, providing users with transparent, data-driven insights that enhance decision-making rather than relying on opaque black-box models.
• Navigating the AI Hype: Dimitrios discussed how the rise of AI has brought both opportunity and noise, emphasizing the importance of high-quality data and a clear understanding of AI’s practical applications in pharma.
• Future Vision: Intelligencia AI aims to become the gold standard in drug development risk assessment, expanding its therapeutic coverage and geographic reach, particularly into Asia.

//

Sponsors:

Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership.

www.FrontLines.io

The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe.

www.GlobalTalent.co